Secondary endpoints of phase II/III study confirm clear benefits from treatment with removab® for patients with malignant ascites

(lifePR) Bad Homburg v.d.H., 17.07.2007, Fresenius today announced that further secondary endpoint data from a phase II/III study with removab^® (catumaxomab) in patients with malignant ascites confirm clear benefits for patients treated with the antibody. Trial data show that removab significantly increases time to tumor progression and has a positive influence on overall survival time. Moreover, a prolonged interval between punctures was seen in the removab group compared to the control group and this effect was also observed beyond the end of study.

The results of the randomized study include treatment data from 258 patients with malignant ascites caused by various cancers. Most patients had latestage disease with a median life expectancy of two to three months. The primary endpoint of the study had already demonstrated that patients receiving removab had a fourfold increased puncture-free survival over a therapy with puncture alone (median 46 vs. 11 days, p

Weitere Meldungen dieses Unternehmens

• 11.05.2012 - Fresenius SE & Co. KGaA Annual General Meeting
• 11.05.2012 - Hauptversammlung der Fresenius SE & Co. KGaA
• 11.05.2012 - Fresenius schließt Kapitalerhöhung erfolgreich ab
• 03.05.2012 - Ausgezeichneter Start in das Geschäftsjahr
• 26.04.2012 - Fresenius unterbreitet Angebot zum Erwerb der Rhön-Klinikum AG...
• 09.03.2012 - Fresenius Announces Management Board Changes